Granules India Limited — Investor Meet, 19-11-2025: Analysts/Institutional Investor Meet/Con. Call Updates

Granules India reported strong Q2 FY'26 results: revenue grew 34% YoY to Rs. 1,297 crore, with EBITDA at Rs. 278 crore (21.5% margin), despite Ascelis Peptides' Rs. 20 crore loss. Gagillapur FDA remediation is in final stages; a January 2026 meeting is scheduled. Crucially, the Genome Valley facility received FDA approval, adding 10 billion doses capacity and strengthening finished dosage. Ascelis Peptides aims for PAT profitability by Q4 FY'26. Management is confident in returning to double-digit growth from FY'27, leveraging new capacities, US market strength, and high-value segments.